Rigel Pharmaceuticals
RIGL · United States
Share price · RIGL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RIGL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+4.4%
- 6 Nov 2026-13.3%
- 5 Nov 2026-10.9%
- 3 Nov 2026-3.3%
Nothing announced by RIGL that day or the session before.
- 7 Oct 2026+4.1%
Nothing announced by RIGL that day or the session before.
- 14 Sep 2026-4.0%
Nothing announced by RIGL that day or the session before.
- 14 Aug 2026+4.4%
Nothing announced by RIGL that day or the session before.
- 22 Jun 2026+8.6%
Nothing announced by RIGL that day or the session before.
- 13 May 2026+9.4%
- 12 May 2026+12.1%
Share of unusual movement by asset
For each asset, the share of RIGL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
fostamatinib(Tavalisse) | Approved | Spleen tyrosine kinase (Syk)Small molecule | Immune Thrombocytopenia |
| Approved | Mutant IDH1Small molecule | Acute Myeloid LeukemiaGlioma Relapsed/Refractory Acute Myeloid Leukemia | |
| Approved | RETSmall molecule | Non-Small Cell Lung Cancer | |
Vepdegestrant(Veppanu) | Approved | Estrogen receptorSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
| Phase 1/2 | IRAK1/IRAK4Small molecule | Myelodysplastic Syndromes |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (2)
March 2027 (1)
What to watch
2029 (2)
June 2029 (1)
What to watch
August 2029 (1)
What to watch
2030 (1)
September 2030 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $81M | $18M | $47M+ $53M short-term inv. | —$35M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $79M | — | $61M+ $35M short-term inv. | —$31M operating cash flow | report ↗ |
| 2026-Q1 | $59M | — | $24M+ $122M short-term inv. | —$2.7M operating cash flow | report ↗ |
| 2025-Q3 | $69M | $7.3M | $49M+ $89M short-term inv. | —$24M operating cash flow | report ↗ |
| 2025-Q2 | $102M | $6.8M | $53M+ $55M short-term inv. | —$31M operating cash flow | report ↗ |
| 2025-Q1 | $53M | $8.4M | $46M+ $31M short-term inv. | —-$0.9M operating cash flow | report ↗ |
| 2024-Q3 | $55M | $6.2M | $52M+ $9.4M short-term inv. | —$22M operating cash flow | report ↗ |
| 2024-Q2 | $37M | $5.5M | $36M+ $13M short-term inv. | $1.0M$0.3M operating cash flow | report ↗ |
| 2024-Q1 | $30M | $6.0M | $26M+ $24M short-term inv. | $8.3M-$5.0M operating cash flow | report ↗ |
| 2023-Q3 | $28M | $6.5M | $45M+ $17M short-term inv. | $5.7M-$1.4M operating cash flow | report ↗ |
| 2023-Q2 | $27M | $4.8M | $49M+ $16M short-term inv. | $6.6M$5.9M operating cash flow | report ↗ |
| 2023-Q1 | $26M | $10M | $40M+ $18M short-term inv. | $14M-$4.1M operating cash flow | report ↗ |
| 2022-Q3 | $22M | $15M | $30M+ $52M short-term inv. | $19M-$13M operating cash flow | report ↗ |
| 2022-Q2 | $30M | $15M | $27M+ $62M short-term inv. | $13M-$13M operating cash flow | report ↗ |
| 2022-Q1 | $17M | $15M | $25M+ $83M short-term inv. | $27M-$26M operating cash flow | report ↗ |
| 2021-Q3 | $22M | $18M | $30M+ $113M short-term inv. | $21M-$10M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $294M | — | $41M+ $114M short-term inv. | —$76M operating cash flow | report ↗ |
Rigel reported full-year 2025 total revenues of $294.28M, up 64.1% YoY, with net product sales of $232.0M and contract revenues of $62.3M. R&D expense was $33.295M, and cash, cash equivalents and short-term investments were $155.0M at year-end. The company reported net income of $367.0M for the full year, including a $245.9M non-cash deferred income tax benefit; fourth-quarter net income was $268.1M.
Rigel guided to 2026 total revenues of approximately $275–$290M, including net product sales of $255–$265M and contract revenues of $20–$25M, with positive full-year net income. Clinically, enrollment is ongoing in the dose expansion phase of the Phase 1b study of R289 in lower-risk MDS, with completion and recommended Phase 2 dose selection expected in the second half of 2026 and preliminary data anticipated by end of 2026; updated R289 dose-escalation data were presented at ASH 2025. The company also presented olutasidenib data at ASH, enrolled the first patient in the CONNECT Phase 2 TarGeT-D study, presented pralsetinib data at NACLC and ASCO-GI, received FDA approval of a GAVRETO labeling update adding a boxed warning about serious infections, published five-year olutasidenib results, and added Michael P. Miller to its board of directors.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $179M | $23M | $57M+ $21M short-term inv. | —$31M operating cash flow | report ↗ |
| 2023-FY | $117M | $25M | $33M+ $24M short-term inv. | $6.3M-$5.7M operating cash flow | report ↗ |
| 2022-FY | $120M | $60M | $24M+ $34M short-term inv. | $15M-$74M operating cash flow | report ↗ |
| 2021-FY | $149M | $65M | $19M+ $106M short-term inv. | $4.5M$5.9M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($306K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise | 694 | $12.70 | $9K | Form 4 |
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise | 620 | $18.70 | $12K | Form 4 |
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise | 2,000 | $24.20 | $48K | Form 4 |
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise | 1,286 | $24.20 | $31K | Form 4 |
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise (derivative) | 694 | — | — | Form 4 |
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise (derivative) | 620 | — | — | Form 4 |
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise (derivative) | 2,000 | — | — | Form 4 |
| 2026-09-02 | Schorno Dean L · EVP & Chief Financial Officer | Option exercise (derivative) | 1,286 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 148 reporting institutions held 15.9M shares ($394.0M, 84.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 1,768,907 | $47.8M |
| 2 | ARMISTICE CAPITAL, LLC | 1,280,000 | $34.6M |
| 3 | STATE STREET CORP | 1,120,238 | $30.3M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 764,193 | $20.7M |
| 5 | MARSHALL WACE, LLP | 598,378 | $16.2M |
| 6 | AMERICAN CENTURY COMPANIES INC | 544,431 | $14.7M |
| 7 | D. E. Shaw & Co., Inc. | 445,678 | $12.1M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 440,626 | $11.9M |
| 9 | GOLDMAN SACHS GROUP INC | 439,101 | $11.9M |
| 10 | TWO SIGMA INVESTMENTS, LP | 405,807 | $11.0M |
| 11 | DIMENSIONAL FUND ADVISORS LP | 379,541 | $10.3M |
| 12 | Qube Research & Technologies Ltd | 343,897 | $9.3M |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 338,441 | $9.2M |
| 14 | Nuveen, LLC | 337,427 | $9.1M |
| 15 | MILLENNIUM MANAGEMENT LLC | 264,410 | $7.1M |